OCUP OCUP

Ocuphire Pharma Stock Price

3.52
0.00 (0.0%)
3.52
Volume 9
Bid Price 3.44
Ask Price 3.60
News -
Day High

Low
3.1901

52 Week Range

High
13.812

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Ocuphire Pharma Inc OCUP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.52 07:23:35
Open Price Low Price High Price Close Price Prev Close
3.52
Trades Volume Avg Volume 52 Week Range
2 9 - 3.1901 - 13.812
Last Trade Time Type Quantity Stock Price Currency
08:01:20 1 $ 3.52 USD

Period:

Draw Mode:

Ocuphire Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 66.34M 18.85M 17.35M $ - $ - -5.28 -0.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 15.30k 8.40%

more financials information »

Ocuphire Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OCUP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.673.7173.493.62175,236-0.15-4.09%
1 Month3.794.083.43863.71256,293-0.27-7.12%
3 Months4.065.503.19014.102,033,247-0.54-13.3%
6 Months3.905.503.19014.191,072,590-0.38-9.74%
1 Year7.2513.8123.19014.821,000,877-3.73-51.45%
3 Years5.9313.8123.19014.83849,769-2.41-40.64%
5 Years5.9313.8123.19014.83849,769-2.41-40.64%

Ocuphire Pharma Description

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.


Your Recent History
NASDAQ
OCUP
Ocuphire P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.